

4 October 2024

### **Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)**

This notice is given by PolyNovo Limited (**PolyNovo** or **Company**) under section 708A(5)(e) of the Corporations Act 2001(Cth) (**Act**).

The Company advises that it has issued 64,022 fully paid ordinary shares (collectively, **Securities**), as disclosed in the Appendix 2A lodged with ASX and announced on 30 September 2024, using the Company's existing placement capacity under ASX listing rule 7.1.

The Company further advises:

- (a) that the Securities the subject of this notice were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this notice is being given under section 708A(5)(e) of the Act;
- (c) the Company, as at the date of this notice, has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Act.

As at the date of this notice there is no information to be disclosed which is excluded information (of the type referred to in section 708A(7) of the Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

Authority:

This announcement has been authorised by PolyNovo General Counsel & Company Secretary, Lior Harel.

### **About PolyNovo®**

PolyNovo is a disruptive ASX 200 medical technology company, based out of Melbourne, Australia. Its products simplify management of acute complex wounds, redefining healing with meaningfully differentiated patient outcomes across multiple wound etiologies. After treating 50,000+ patients across 41 countries, the company is investing for growth via new products, indications, and markets with a view to treat millions more. For more information see [polynovo.com](https://polynovo.com)

### **About NovoSorb®**

NovoSorb BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. NovoSorb is a novel range of bio-resorbable polymers that can be produced in many formats including film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.